By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



5 Science Park
395 Winchester Avenue
New Haven  Connecticut  06511  U.S.A.
Phone: 203-535-1456 Fax: n/a


Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.

Key Statistics

Ownership: Private

Web Site: Arvinas
Employees: n/a


Company News
Arvinas Appoints Dr. John Houston As President Of Research And Development And Chief Scientific Officer 1/5/2017 7:47:50 AM
Arvinas Presents Data On Oral Estrogen Receptor PROTAC Degrader At 2016 San Antonio Breast Cancer Symposium 12/9/2016 6:53:12 AM
Arvinas Collaborators Present Data On BET PROTAC Degraders At 2016 American Society of Hematology Annual Meeting 12/6/2016 8:47:43 AM
Arvinas Presents Data On Its BET PROTAC Degraders At 2016 European Organization for Research and Treatment of Cancer-NCI-AACR Symposium 11/29/2016 9:24:02 AM
Arvinas Publishes First Peer-Reviewed, In Vivo Data From Its Proprietary PROTAC Technology 6/7/2016 10:51:27 AM
Arvinas To Present Data At The 2016 AACR Annual Meeting 4/14/2016 8:59:28 AM
Arvinas Appoints Angela Shen As Chief Medical Officer 3/2/2016 6:30:17 AM
Arvinas Presents Data At The 2015 American Society of Hematology Annual Meeting 12/3/2015 7:38:08 AM
Arvinas Secures $41.6 Million Series B Financing - Appoints New Board Members 10/21/2015 10:00:42 AM
Arvinas Inks $300 Million Deal With Genentech (RHHBY) Over Protein Degradation Technology 10/1/2015 6:30:24 AM